Nomogram for predicting neutropenia in patients with esophageal, gastric, or colorectal cancer treated by chemotherapy in the first cycle.

IF 2.3 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY International Journal of Biological Markers Pub Date : 2024-03-01 Epub Date: 2024-01-30 DOI:10.1177/03936155241228304
Tian Tian, Wenjun Hu, Jiqing Hao
{"title":"Nomogram for predicting neutropenia in patients with esophageal, gastric, or colorectal cancer treated by chemotherapy in the first cycle.","authors":"Tian Tian, Wenjun Hu, Jiqing Hao","doi":"10.1177/03936155241228304","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Development and validation of a predictive model including serum vitamin concentration to estimate the risk of chemotherapy-induced grade 3/4 neutropenia in esophageal cancer, gastric cancer, or colorectal cancer patients who receive the first cycle of chemotherapy.</p><p><strong>Methods: </strong>Data from 535 patients treated at the Affiliated Fuyang People's Hospital of Anhui Medical University from January 1, 2020, to March 2, 2022, were used to derive the predictive model. Least absolute shrinkage and selection operator regression analysis was performed to screen potential risk characteristics, and multivariate logistic regression was utilized to investigate efficient factors associated with chemotherapy-induced neutropenia. A nomogram was constructed using this logistic model. This nomogram was then tested on a temporal validation cohort containing 212 consecutive patients.</p><p><strong>Results: </strong>In the cohort of all 747 eligible patients, grade 3/4 neutropenia incidence was 45.2%. Age, Eastern Cooperative Oncology Group-performance status, neutrophil count, serum albumin, and hemoglobin data were entered into the final model. The performance of the final predictive nomogram was assessed by the area under the receiver operating characteristic curve in both the development and validation datasets. The calibration curves indicated that the estimated risks were accurate. Decision curve analysis for the predictive model exhibited improved clinical practicality.</p><p><strong>Conclusion: </strong>In the present study, we established an accessible risk predictive model and identified valuable serum vitamin concentration parameters associated with chemotherapy-induced neutropenia. The predictive model may improve the grade 3/4 neutropenia risk prediction in patients with gastrointestinal malignancies who receive oxaliplatin- and fluoropyrimidine-based chemotherapy and help physicians make appropriate decisions for disease management.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155241228304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Development and validation of a predictive model including serum vitamin concentration to estimate the risk of chemotherapy-induced grade 3/4 neutropenia in esophageal cancer, gastric cancer, or colorectal cancer patients who receive the first cycle of chemotherapy.

Methods: Data from 535 patients treated at the Affiliated Fuyang People's Hospital of Anhui Medical University from January 1, 2020, to March 2, 2022, were used to derive the predictive model. Least absolute shrinkage and selection operator regression analysis was performed to screen potential risk characteristics, and multivariate logistic regression was utilized to investigate efficient factors associated with chemotherapy-induced neutropenia. A nomogram was constructed using this logistic model. This nomogram was then tested on a temporal validation cohort containing 212 consecutive patients.

Results: In the cohort of all 747 eligible patients, grade 3/4 neutropenia incidence was 45.2%. Age, Eastern Cooperative Oncology Group-performance status, neutrophil count, serum albumin, and hemoglobin data were entered into the final model. The performance of the final predictive nomogram was assessed by the area under the receiver operating characteristic curve in both the development and validation datasets. The calibration curves indicated that the estimated risks were accurate. Decision curve analysis for the predictive model exhibited improved clinical practicality.

Conclusion: In the present study, we established an accessible risk predictive model and identified valuable serum vitamin concentration parameters associated with chemotherapy-induced neutropenia. The predictive model may improve the grade 3/4 neutropenia risk prediction in patients with gastrointestinal malignancies who receive oxaliplatin- and fluoropyrimidine-based chemotherapy and help physicians make appropriate decisions for disease management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预测食管癌、胃癌或结直肠癌第一周期化疗患者中性粒细胞减少的提名图。
目的:开发并验证一种包括血清维生素浓度在内的预测模型,以估计食管癌、胃癌或结直肠癌患者化疗引起的 3/4 级中性粒细胞减少症的风险:建立并验证包括血清维生素浓度在内的预测模型,以估计接受第一周期化疗的食管癌、胃癌或结直肠癌患者化疗引起的3/4级中性粒细胞减少症的风险:采用安徽医科大学附属阜阳人民医院 2020 年 1 月 1 日至 2022 年 3 月 2 日期间收治的 535 例患者的数据来推导预测模型。通过最小绝对收缩和选择算子回归分析来筛选潜在的风险特征,并利用多变量逻辑回归来研究与化疗引起的中性粒细胞减少症相关的有效因素。利用该逻辑模型构建了一个提名图。然后在一个包含 212 名连续患者的时间验证队列中对该提名图进行了测试:在所有 747 名符合条件的患者中,3/4 级中性粒细胞减少症的发生率为 45.2%。年龄、东部合作肿瘤学组表现状态、中性粒细胞计数、血清白蛋白和血红蛋白数据均已输入最终模型。最终预测提名图的性能通过开发数据集和验证数据集的接收者操作特征曲线下面积进行评估。校准曲线表明,估计的风险是准确的。预测模型的决策曲线分析显示临床实用性有所提高:在本研究中,我们建立了一个易于使用的风险预测模型,并确定了与化疗引起的中性粒细胞减少症相关的有价值的血清维生素浓度参数。该预测模型可改善接受奥沙利铂和氟嘧啶化疗的胃肠道恶性肿瘤患者的 3/4 级中性粒细胞减少症风险预测,并帮助医生做出适当的疾病管理决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Biological Markers
International Journal of Biological Markers 医学-生物工程与应用微生物
CiteScore
4.10
自引率
0.00%
发文量
43
期刊介绍: IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.
期刊最新文献
Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma. Inflammatory markers related to survival in breast cancer patients: Peru. Alteration of lncRNA RHPN1-AS1 predicts clinical prognosis and regulates the progression of bladder cancer via modulating miR-485-5p. Serum LINC00339 is a promising biomarker for prognosis prediction of nasopharyngeal carcinoma. Value of the HOTAIR expression assay in predicting therapy target in hepatocellular carcinoma: A meta-analysis and bioinformatics analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1